Wollheim F A, Lindroth Y, Sjöblom K G
Rheumatol Rehabil. 1978;Suppl:78-83. doi: 10.1093/rheumatology/xvii.suppl.78.
Ketoprofen, 50+50+100 mg, was compared to naproxen, 250+250+250 mg, in a double-blind, cross-over twice 4-weeks' study on patients with RA. There was no significant difference in the effect on morning stiffness, pain at rest, joint count, grip strength or ESR. Among 28 patients 10 preferred ketoprofen and 7 naproxen. Two ketoprofen and 1 naproxen periods were interrupted owing to intolerable side-effects. Twenty of the patients experienced some side-effect from at least one drug. The most common complaints were gastrointestinal, seen in 12 patients on ketoprofen and 9 on naproxen. Most side-effects were mild. No abnormality in blood morphology, liver function tests, serum creatinine or fasting blood glucose was observed. No occult bleeding was detected on routine stool examination.
在一项针对类风湿性关节炎患者的双盲、交叉、为期两个4周的研究中，对酮洛芬（50+50+100毫克）与萘普生（250+250+250毫克）进行了比较。在对晨僵、静息痛、关节计数、握力或红细胞沉降率的影响方面，两者无显著差异。在28例患者中，10例更喜欢酮洛芬，7例更喜欢萘普生。由于无法耐受的副作用，有两个酮洛芬疗程和一个萘普生疗程被中断。20例患者至少从一种药物中出现了一些副作用。最常见的主诉是胃肠道问题，酮洛芬组有12例患者出现，萘普生组有9例患者出现。大多数副作用较轻。未观察到血液形态学、肝功能检查、血清肌酐或空腹血糖有异常。常规粪便检查未发现隐匿性出血。
